Back

Acoramidis for ATTR cardiomyopathy: value, access, and the duty to treat

European Heart Journal - Quality of Care and Clinical Outcomes

5 June 2026
Organised by: Logo
Read full article
ESC Journals VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Contributors

Daniela Di Lisi
Daniela Di Lisi

Author

Daniela Tomasoni
Daniela Tomasoni

Author

Spedali Civili, University Of Brescia Brescia , Italy

Alberto Aimo
Alberto Aimo

Author

You may be interested in
thumbnail
Congress Session
ATTRibutes of change: advances in treating and monitoring ATTR-CM
17 May 2025
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitors in patients with transthyretin amyloid cardiomyopathy - results from a patient series
20 May 2023
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025
thumbnail
Congress Presentation
Acoramidis reduces days lost to death and/or cardiovascular-related hospitalization, preserving time alive outside the hospital in participants with ATTR-CM: results from ATTRibute-CM
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources